Vesalius Therapeutics is changing the approach to drug research for common diseases by treating each disease as multiple diseases with different biology. Their technology creates a molecular human avatar and digital human avatar to analyze differences within diseases and match treatments to patients. The startup recently secured a $80 million deal with GSK for a small molecule developed from their platform technology to target Parkinson’s disease. Vesalius is also researching immunological diseases and is open to partnerships in other therapeutic areas. The goal is to redefine disease and improve drug development outcomes with a human-based approach.
Source link
GSK Wagers $80M on a Tech Platform and Parkinson’s Drug from Flagship-Founded Vesalius
